Approaching clinical proteomics: current state and future fields of application in fluid proteomics

Apweiler, Rolf; Aslanidis, Charalampos; Deufel, Thomas; Gerstner, Andreas O. H.; Hansen, Jens; Hochstrasser, Dennis; Kellner, Roland; Kubicek, Markus; Lottspeich, Friedrich; Maser, Edmund; Mewes, Hans‐Werner; Meyer, Helmut E.; Müllner, Stefan; Mutter, Wolfgang; Neumaier, Michael; Nollau, Peter; Nothwang, Hans Gerd; Pontén, Fredrik; Radbruch, Andreas; Reinert, Knut; Rothe, Gregor; Stockinger, Hannes; Tárnok, Attila; Taussig, Mike; Thiel, Andreas; Thiery, Joachim; Ueffing, Marius; Valet, G.; Vandekerckhove, Joël; Verhuven, Wiltrud; Wagener, Christoph; Wagner, Oswald; Schmitz, Gerd

doi:10.1515/cclm.2009.167

Cited by 120 publications

(73 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, there is an urgent need for standardization of specimen collection/processing, quantitation, and setting strategies for managing biomarkers after their detection [137]. Progress also relies on the establishment of Standard Operating Procedures (SOPs) for the appropriate selection of patients and specimens, thus decreasing the complexity of samples to be analyzed [138]. In this regard, the Human Plasma Proteome Project (HPPP) (see http://www.hupo.org/initiatives/ plasma-proteome-project/) is an initiative conceived and launched by the Human Proteome Organization (HUPO) (available at http:// www.hupo.org/) to solve matters related to pre-analytical variability and to make attempts to establish SOPs [139].…”

Section: Blood Prospective Candidate Biomarkersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

105

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD

show abstract

Section: Blood Prospective Candidate Biomarkersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

105

View full text Add to dashboard Cite

show abstract

“…Bound to high-abundance proteins such as albumin, it represents a fingerprint of the molecular events taking place within different organs or tissues related to the presence of cancers but also modification to their close micro-environment [45,46]. Therefore, the analysis of protein imbalances in the serum can be directly related to, and indicative of, disease states [47][48][49][50]. Due to the complex composition of the serum, different tools can be employed for the detection of proteins levels, such as electrophoresis or 2D-SDS-PAGE.…”

Section: Biophotonicsmentioning

confidence: 99%

Improved protocols for vibrational spectroscopic analysis of body fluids

Bonnier¹,

Petitjean

Baker

et al. 2013

Journal of Biophotonics

View full text Add to dashboard Cite

The applications of vibrational spectroscopy to the examination of human blood serum are explored. Although FTIR spectra can be recorded in aqueous solutions at (gelatin) concentrations as low as 100 mg/L, the high-wavenumber region remains obscured by water absorption. Using Raman spectroscopy, high quality spectra of gelatine solutions as low as 10 mg/L can be achieved, also covering the high-wavenumber regions. In human serum, spectral profiles are weak and partially obscured by water features. Dried deposits are shown to be physically and chemically inhomogeneous resulting in reduced measurement reproducibility. Concentration of the serum using commercially available centrifugal filter devices results in an improvement in the spectral intensity and quality. Additionally, in Raman spectroscopy, reduced background and significantly enhanced signal collection is achievable by measurement in an inverted geometry. The improved protocols for spectroscopic measurement of human serum are applicable to a range of bodily fluids and should accelerate potential clinical applications

show abstract

“…Almost all biologic fluids (serum, plasma, urine, saliva, cerebrospinal, synovial, bronchoalveolar lavage, and amniotic fluids (AF), as well as tissue samples have been analyzed in search of specific target proteins that may act as possible diagnostic or therapeutic markers. Almost all fields of clinical medicine have profited from the characterization of proteins and their subproteomic profiles, such as the phosphoproteomes, in different tissues and medical conditions, although their use in everyday clinical practice remains a challenge (29)(30)(31).…”

Section: Tools Used In Proteomics Analysismentioning

confidence: 99%